Elanco Animal Health (ELAN) Scheduled to Post Quarterly Earnings on Wednesday

Elanco Animal Health (NYSE:ELAN) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.26 per share for the quarter. Elanco Animal Health has set its Q1 guidance at $0.25-0.28 EPS and its FY24 guidance at $0.87-0.95 EPS.Investors interested in listening to the company’s conference call can do so using this link.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.02). The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.19 earnings per share. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Stock Down 2.0 %

ELAN opened at $13.27 on Tuesday. Elanco Animal Health has a 12 month low of $7.88 and a 12 month high of $16.88. The business has a 50-day moving average of $15.02 and a two-hundred day moving average of $13.98. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. The stock has a market capitalization of $6.55 billion, a price-to-earnings ratio of -5.31, a price-to-earnings-growth ratio of 1.42 and a beta of 1.34.

Insider Buying and Selling at Elanco Animal Health

In other news, Director R David Hoover acquired 20,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the acquisition, the director now directly owns 185,000 shares of the company’s stock, valued at approximately $2,985,900. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Barclays lifted their target price on Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Finally, The Goldman Sachs Group upped their price target on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.71.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.